Video
21 Jun 2021

White Paper > Highly Potent Compound Pediatric Dosage Forms

AuthorsDr. Oliver Schinzinger, Head of Pharmaceutical Development, CordenPharma Plankstadt
Dr. Eva Fahrländer, Scientific Lead, Formulation Development, CordenPharma Plankstadt
Dr. Christoph Rott, Head of Formulation Development, CordenPharma Plankstadt

Get informed about Pediatric Dosage Form Considerations for Highly Potent Compounds in this CordenPharma whitepaper discussing the benefits of Mini-Tablets as an effective pediatric dosage form. Topics include:

  • Age Appropriate Dosage Forms
  • Flexible & Accurate Dosing
  • Excipients & Taste Masking
  • Manufacture & In-Process Control Testing
  • Challenges Transitioning from Tablets to Mini-Tablets 

Content provided by our supplier

Corden Pharma International GmbH

  • DE
  • 2015
    On CPHI since
  • 4
    Certificates
  • 1000 - 4999
    Employees
Company types
CMO/CDMO

Other Content from Corden Pharma International GmbH (17)